Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing
Reexamination Certificate
2002-11-27
2009-08-04
Zeman, Robert A (Department: 1645)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
C424S093400, C424S184100, C435S007320, C435S007310
Reexamination Certificate
active
07569209
ABSTRACT:
Method for early differential diagnosis and detection, for prognosis and for assessing the severity and for therapy-accompanying assessment of the course of sepsis and sepsis-like systemic infections, in which, preferably with determination of at least one further parameter suitable for sepsis diagnosis, the amount of S100B in a biological fluid of a patient in whom a sepsis is present or sepsis is suspected is determined and conclusions with regard to the presence, the expected course, the severity and/or the success of initiated measures for the therapy of sepsis are drawn from the determined amount of S100B.
REFERENCES:
patent: 5639617 (1997-06-01), Bohuon
patent: 5660994 (1997-08-01), Bruder-Heid et al.
patent: 198 47 690 (2000-04-01), None
patent: 101 19 804 (2002-10-01), None
patent: 101 30 985 (2003-01-01), None
patent: 101 31 922 (2003-01-01), None
patent: 1 318 403 (2004-07-01), None
patent: WO 00/22439 (2000-04-01), None
patent: WO 02/085937 (2002-10-01), None
patent: WO 03/002600 (2003-01-01), None
patent: WO 03/005035 (2003-01-01), None
Hauschild et al. (British Journal of Dermatology, 1999, vol. 140 No. 6, pp. 1065-1071).
Bosserhoff et al. (Cancer Research, 1997, vol. 57, pp. 3149-3153).
Aird, “The Hematologic System as a Marker of Organ Dysfunction in Sepsis,”Mayo Clin, Proc., 78:869-881, 2003.
Assicot, et al., “High Serum Procalcitonin Concentrations in Patients with Sepsis and Infection,”Lancet, 341(8844):515-518, 1993.
Beishuizen et al. , “Endogenous Mediators in Sepsis and Septic Shock,”Advances Clin. Chem., 33:55-131, 1999.
Bertsch et al., “Protein S-100B: A Serum Marker for Ischemic and Infectious Injury of Cerebral Tissue,”Clin. Chem. Lab Med., 39(4):319-323, 2001.
Carrigan et al., “Toward Resolving the Challenges of Sepsis Diagnosis,”Clin. Chem., 50(8):1301-1314, 2004.
Donato, “Functional Roles of S100 Proteins, calcium-Binding Proteins of the EF-Hand Type,”Biochim. Biophys. Acta, 1450:191-231, 1999.
Gabay and Kushner, “Acute-Phase Proteins and Other Systemic Responses to Inflammation,”New Engl. J. Med., 340(6):448-454, 1999.
Hotchkiss and Karl, “The Pathophysiology and Treatment of Sepsis,”N. Engl. J. Med., 348(2):138-150, 2003.
Jäckel, “S-100β-Protein im Serum als Tumormarker beim malignen Melanom,” Hautarzt, 50:250-256, 1999.
Karzai, et al., “Procalcitonin—A New Indicator of the Systemic Response to Severe Infections,”Infection, 25:3-8, 1997.
Kerkhoff et al., “Novel Insights Into Structure and Function of MRP8 (S100A8) and MRP14 (S100A9),”Biochim. Biophys. Acta, 1448:200-211, 1998.
Marshall et al., “Measures, Markers, and Mediators: Toward a Staging System for Clinical Sepsis. A Report of the Fifth Toronto Sepsis Roundtable, Toronto, Ontario, Canada, Oct. 25-26, 2000,”Crit. Care Med., 31(5):1560-1567, 2003 (Abstract only).
Nagamatsu et al., “Cerebrospinal Fluid Levels of S-100b Protein and Neuron-Specific Enolase in Chronic Inflammatory Demyelinating Polyneuropathy,”Acta Neurol. Scand., 91:483-487, 1995.
Oberholzer et al., “Sepsis Syndromes: Understanding the Role of Innate and Acquired Immunity,”Shock, 16(2):83-96, 2001 (Abstract only).
Oczenski et al., “Procalcitonin: A New Parameter for the Diagnosis of Bacterial Infection in the Peri-Operative Period,”Eur. J. Anaesthesiol., 15:202-209, 1998.
Passey et al., “S100A8: Emerging Functions and Regulation,”J. Leukoc. Biol., 66:549-556, 1999.
Redl et al., “Procalcitonin Release Patterns in a Baboon Model of Trauma and Sepsis: Relationship to Cytokines and Neopterin,”Crit. Care Med., 28(11):3659-3663, 2000.
Redl and Schlag, “Non-Human Primate Models of Sepsis,”Sepsis, 2:243-253, 1998.
Reinhart et al., “Sepsis Und Spetischer Schcok,”Intensivmedizin, 756-760, 2001.
International Search Report for EPO Application No. 01128849.5, mailed Jun. 4, 2002.
International Search Report for PCT Application No. PCT/EP 02/13393, mailed Nov. 27, 2002.
B.R.A.H.M.S. Aktiengesellschaft
Heslin Rothenberg Farley & & Mesiti P.C.
Zeman Robert A
LandOfFree
Method for diagnosis of sepsis by determination of S100B does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for diagnosis of sepsis by determination of S100B, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for diagnosis of sepsis by determination of S100B will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4105278